Wildcat Capital Management LLC Takes Position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

Wildcat Capital Management LLC acquired a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 281,859 shares of the company's stock, valued at approximately $4,053,000. Centessa Pharmaceuticals accounts for about 2.2% of Wildcat Capital Management LLC's investment portfolio, making the stock its 6th biggest holding. Wildcat Capital Management LLC owned approximately 0.21% of Centessa Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth $31,000. Barclays PLC increased its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Centessa Pharmaceuticals during the first quarter valued at $147,000. BNP Paribas Financial Markets bought a new stake in Centessa Pharmaceuticals in the 4th quarter worth about $162,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Centessa Pharmaceuticals in the 4th quarter worth about $171,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock traded down $0.27 during trading hours on Friday, reaching $15.69. 1,007,312 shares of the company traded hands, compared to its average volume of 772,953. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.00 and a 12-month high of $19.09. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37. The company has a market cap of $2.10 billion, a P/E ratio of -8.67 and a beta of 1.45. The firm has a 50-day moving average price of $13.17 and a 200 day moving average price of $14.46.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. As a group, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mario Alberto Accardi sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total value of $210,000.00. Following the transaction, the insider directly owned 216,485 shares of the company's stock, valued at approximately $3,030,790. The trade was a 6.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of the business's stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $13.61, for a total value of $159,808.62. Following the completion of the transaction, the insider directly owned 122,279 shares in the company, valued at approximately $1,664,217.19. This represents a 8.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 189,398 shares of company stock worth $2,462,692 in the last quarter. 7.09% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Piper Sandler assumed coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price objective for the company. Chardan Capital assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a "buy" rating and a $30.00 price target for the company. Oppenheimer assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target for the company. Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They set a "buy" rating and a $35.00 price target for the company. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.89.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.